Adial Pharmaceuticals appoints Tony Goodman as COO effective Jan 17, 2024

ADIAL PHARMACEUTICALS, INC.

Tony Goodman appointed COO effective Jan 17, 2024; continues as board director.
Compensation $25k/month, must devote ≥75% business time to role.
Will lead strategic growth, clinical development & commercial planning for AD04 (AUD treatment).
Former Chief Business Development Officer at Indivior; helped grow addiction market revenue >$1B.
Appointment via Statement of Work #2 under existing Master Services Agreement with The Keswick Group.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tony Goodman

Chief Operating Officer

ADIL · ADIAL PHARMACEUTICALS, INC.

Effective: 2024-01-17
Filed: January 18, 2024, 6:59 PM ET

Tony Goodman, a director of the Company, is the founder and principal, pursuant to which Mr. Goodman has agreed to serve in the capacity as Chief Operating Officer of the Corporation

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tony Goodman was appointed as Chief Operating Officer at ADIAL PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

Tony Goodman, a director of the Company, is the founder and principal, pursuant to which Mr. Goodman has agreed to serve in the capacity as Chief Operating Officer of the Corporation

View on SEC.gov

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-004505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.